Cantel Medical (Little Falls, New Jersey) has promoted Andrew Krakauer to president/CEO. Krakauer also will become a member of the board of directors. Previously Krakauer has served as executive VP and COO, and since April 2008 as president. The board also appointed Seth Segel, senior VP of strategy and corporate development, to executive VP and Craig Sheldon, senior VP-CFO, to senior VP - CFO and treasurer. In addition, board member George Fotiades was named vice chairman, replacing Alan Hirschfield, who retired from the post on March 18 but remains an active board member. Cantel is a provider of infection prevention and control products in the healthcare market.

Jim Emerson, PhD, has been named VP of etrials Worldwide's (Morrisville, North Carolina) technology and development functions. Previously, Emerson has served as director of computer resources at KPMG in its New York executive office, VP of technology at Pansophic Systems (now part of Computer Associates), president of RTI Software, and senior VP at Marsh USA. etrials provides eClinical software and services to pharmaceutical, biotechnology, medical device, and contract research organizations.

Oxygen Biotherapeutics (Costa Mesa, California) reported the expansion of the company's board of directors with the addition of J. Melville Engle to the board. Engle has raised money on Wall Street, launched hundreds of products, and has a broad management and financial background, including six years at Dey LP, where he was the firm's president/CEO. He has also held senior executive positions with Merck Generics Group and Allergan. Oxygen Biotherapeutics, is developing a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte) and an implantable glucose sensor.

No Comments